✦ LIBER ✦

920 Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase 2 Study

✍ Scribed by Hardacre, Jeffrey M.; Mulcahy, Mary; Small, William; Talamonti, Mark; Obel, Jennifer; Rocha-Lima, Caio S.; Safran, Howard; Lenz, Heinz-Joseph; Chiorean, Elena G.

Book ID: 122755781
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 65 KB
Volume: 142
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(12)64051-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of Algenpantucel-L Immunotherap

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study

✍ Jeffrey M. Hardacre, Mary Mulcahy, William Small, Mark Talamonti, Jennifer Obel, 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 241 KB

Erratum to: Phase II Study of Gemcitabin

Erratum to: Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

✍ Philip Q. Bao; Ramesh K. Ramanathan; Alyssa Krasinkas; Nathan Bahary; Barry C. L 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 107 KB

Phase II Study of Gemcitabine and Erloti

Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer

✍ Philip Q. Bao; Ramesh K. Ramanathan; Alyssa Krasinkas; Nathan Bahary; Barry C. L 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 303 KB